$4.07
7.08% yesterday
Nasdaq, Dec 23, 10:00 pm CET
ISIN
US74017N1054
Symbol
PGEN

Precigen Inc Stock price

$4.07
+0.25 6.54% 1M
+2.59 175.00% 6M
+2.95 263.39% YTD
+3.32 445.50% 1Y
+2.67 190.71% 3Y
-5.84 58.93% 5Y
-27.27 87.01% 10Y
-19.54 82.77% 20Y
Nasdaq, Closing price Tue, Dec 23 2025
-0.31 7.08%
ISIN
US74017N1054
Symbol
PGEN
Industry

Key metrics

Basic
Market capitalization
$1.4b
Enterprise Value
$1.4b
Net debt
positive
Cash
$121.1m
Shares outstanding
353.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
228.2 | 82.9
EV/Sales
223.7 | 81.2
EV/FCF
negative
P/B
34.4
Financial Health
Equity Ratio
45.9%
Return on Equity
-189.2%
ROCE
-77.4%
ROIC
-248.1%
Debt/Equity
2.2
Financials (TTM | estimate)
Revenue
$6.3m | $17.4m
EBITDA
$-105.0m | $-129.5m
EBIT
$-107.7m | $-120.6m
Net Income
$-425.9m | $-316.4m
Free Cash Flow
$-75.6m
Growth (TTM | estimate)
Revenue
59.3% | 342.2%
EBITDA
22.4% | -43.7%
EBIT
23.5% | -27.3%
Net Income
-205.2% | -150.6%
Free Cash Flow
10.3%
Margin (TTM | estimate)
Gross
30.3%
EBITDA
-1,663.5% | -745.4%
EBIT
-1,706.6%
Net
-6,750.1% | -1,820.5%
Free Cash Flow
-1,198.6%
More
EPS
$-1.4
FCF per Share
$-0.2
Short interest
15.1%
Employees
143
Rev per Employee
$30.0k
Show more

Is Precigen Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,085 stocks worldwide.

Precigen Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Precigen Inc forecast:

7x Buy
78%
2x Hold
22%

Analyst Opinions

9 Analysts have issued a Precigen Inc forecast:

Buy
78%
Hold
22%

Financial data from Precigen Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
6.31 6.31
59% 59%
100%
- Direct Costs 4.40 4.40
1% 1%
70%
1.91 1.91
490% 490%
30%
- Selling and Administrative Expenses 63 63
57% 57%
1,006%
- Research and Development Expense 46 46
15% 15%
731%
-105 -105
22% 22%
-1,663%
- Depreciation and Amortization 2.72 2.72
50% 50%
43%
EBIT (Operating Income) EBIT -108 -108
23% 23%
-1,706%
Net Profit -426 -426
205% 205%
-6,749%

In millions USD.

Don't miss a Thing! We will send you all news about Precigen Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Precigen Inc Stock News

Positive
The Motley Fool
22 days ago
San Diego-based Tang Capital Management initiated new stake: up 12,400,000 shares, an estimated $40.8 million Change represents 1.6% of reportable assets under management Post-trade holding: 12,400,000 shares valued at $40.8 million Precigen is not among the fund's top five positions after the trade
Positive
Seeking Alpha
29 days ago
Precigen (PGEN) remains a Buy after PAPZIMEOS' FDA approval and launch, with higher-than-expected pricing and broad label supporting robust revenue potential. A new Pharmakon credit facility extends PGEN's cash runway into at least 2027, with management targeting cash-flow breakeven by the end of 2026. PAPZIMEOS' net price is ~$400,000 per patient annually, and redosing/early-line adoption coul...
Neutral
Seeking Alpha
about one month ago
Precigen, Inc. ( PGEN ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Steven Harasym - VP & Head of Investor Relations Helen Sabzevari - President, CEO & Director Phil Tennant - Chief Commercial Officer Rutul Shah - Chief Operating Officer Harry Thomasian - Chief Financial Officer Conference Call Participants Jason Butler - Citizens JMP Securities, LLC, Research Divis...
More Precigen Inc News

Company Profile

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. The firm focuses on programming biological systems to alleviate disease, remediate environmental challenges, and provide sustainable food and industrial chemicals. It operates through the following segments: PGEN Therapeutics, ActoBio, MBP Titan, Trans Ova and All Other. The PGEN Therapeutics segment is advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders and infectious diseases. The ActoBio segment involves in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The MBP Titan segment comprises of Methane Bioconversion Platform, and associated technologies, personnel, and facilities The Trans Ova segment includes provides advanced reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Head office United States
CEO Helen Sabzevari
Employees 143
Founded 1998
Website precigen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today